Stock Financial Ratios, Dividends, Split History
NRP / Natural Resource Partners L.P. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||351.33|
|Enterprise Value ($M)||1,210.59|
|Book Value ($M)||261.82|
|Book Value / Share||29.74|
|Price / Book||1.34|
|NCAV / Share||-70.46|
|Price / NCAV||-0.52|
|Income Statement (mra) ($M)|
|Revenue Net Including Gain Losson Dispositionof Assets||378,017,000.00|
|Shipping And Handling Revenue||38,900,000.00|
|Equity Method Investment Summarized Financial Information Revenue||40,457,000.00|
|Disposal Group Including Discontinued Operation Revenue||0.00|
|Sales Revenue Net||374,161,000.00|
|Disposal Group Including Discontinued Operations Revenue Oiland Gas||0.00|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||127.14|
|Cash from Investing||3.54|
|Cash from Financing||3.54|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1171486|
|63900P958 63900P903 63900P953 63900P608 63900P908|
|SIC 1221 - Bituminous Coal and Lignite Surface Mining|
Stock splits are used by Natural Resource Partners L.P. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Related News Stories
The week started strong, with MLPs up 1.6% Monday, but then followed up with 4 straight negative days, culminating in a big Friday selloff (-2.6%). Friday was the MLP Index's worst day since March 19th, just a few days after the FERC ruling. It was also the worst week for the index since that same week in March. Unlike that week, there wasn't any big midstream news that led to the drop. The action this week was more related to the macro (i. (38-0)
Midstream overall outperformed and MLPs again led the way, up another 3.1%. The MLP Index is now up 14.4% the last 8 weeks, rallying in 6 of those 8 weeks. Energy and oil prices continue to trade well, with MLPs trying to keep pace with broad energy stocks. News flow was light until Thursday's simplification party. Weaker Canadian and utility performance dragged down the broader AMEI midstream index performance. (42-0)
With the Q1 earnings season at the tail end, April traffic reports from airlines dominated headlines over the past five trading days. Evidently, key airline players like United Continental Holdings (UAL - Free Report) , Delta Air Lines, Inc. (DAL - Free Report) , Southwest Airlines Co. (LUV - Free Report) and GOL Linhas Aereas Inteligentes S.A. (GOL - Free Report) unveiled their respective traffic reports during the week. (9-0)
Natural Resource Partners LP (NRP - Free Report) reported first-quarter 2018 adjusted earnings of $1.16 per unit, missing the Zacks Consensus Estimate of $1.26 by 8%. The figure improved from the year-ago quarter’s tally. Total Revenues In the quarter under review, Natural Resource’s total revenues of $89 million missed the Zacks Consensus Estimate of $99 million by 10.1% and were in line with the year-ago quarter’s figure. (23-0)
One of the bigger risks in the markets is index risk. This is because the market for stocks continues to consolidate into fewer and fewer shares of listed companies. It hit a peak in the 1990s at around 8,000 stocks in the U.S. market, but that number now is less than 4,000 individual listed stocks. Less opportunity and more concentration of risk. (169-0)
as of ET